Last reviewed · How we verify
Bupivacaine 0.125% Injectable Solution
At a glance
| Generic name | Bupivacaine 0.125% Injectable Solution |
|---|---|
| Also known as | Marcain |
| Sponsor | Bozyaka Training and Research Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Spinal Anesthesia For Enhanced Recovery After Liver Surgery (NA)
- Dosage of Epidural Morphine in Elderly Patients (PHASE4)
- Ultrasound Guided Bilateral Erector Spinae Block Versus Caudal in Lumbar Spine Surgeries (NA)
- Spinal Analgesia as Fast Track Painless Labor
- Bilateral Retromuscular Rectus Sheath Block Catheters Usage for Early Postoperative Analgesia After Laparotomic Gastrectomy. (NA)
- U/S-guided Continuous Quadratus Lumborum Block III in Percutaneous Nephrolithotomy (NA)
- ESP Block VS TAP in Laparoscopic Hysterectomy (PHASE3)
- The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: